🇺🇸 FDA

Intelligence · Clinical Pipeline

Sarepta Therapeutics Pipeline

All ClinicalTrials.gov programs at Sarepta Therapeutics — phase, modality, and trial IDs.

Programs
46

Quick answer

Sarepta Therapeutics has 46 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  2. Casimersen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial

  3. Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  4. ETEPLIRSEN (AVI-4658)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  5. Eteplirsen

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 3 small molecule active

    2 trials

  6. PREDNISONE, SRP-9003, PREDNISONE, PREDNISONE

    Sarepta Therapeutics

    Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy

    phase 3 small molecule active

    1 trial

  7. SRP-4045

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    2 trials

  8. SRP-9003

    Sarepta Therapeutics

    Limb-girdle Muscular Dystrophy

    phase 3 mab active

    2 trials

  9. SRP-9005

    Sarepta Therapeutics

    Muscular Dystrophies, Limb-Girdle

    phase 3 mab terminated

    1 trial

  10. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  11. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    7 trials

  12. eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule completed

    2 trials

  13. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  14. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  15. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule completed

    1 trial

  16. AVI-4658 (PMO)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  17. AVI-4658 for Injection

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  18. AVI-5126

    Sarepta Therapeutics

    Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  19. Amondys 45

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  20. Eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  21. Placebo

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  22. Placebo - Sodium Chloride 9 mg/ml (0.9%) - Solution for injection, ARO-DM1

    Sarepta Therapeutics

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  23. RESTEN-MP

    Sarepta Therapeutics

    Coronary Artery Disease

    phase 2 small molecule completed

    2 trials

  24. SODIUM CHLORIDE, ARO-DUX4

    Sarepta Therapeutics

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

  25. SRP-5051

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 small molecule terminated

    2 trials

  26. SRP-9003

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2E

    phase 2 gene therapy terminated

    1 trial

  27. SRP-9004

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2D

    phase 2 gene therapy completed

    1 trial

  28. VESLETEPLIRSEN(SRP-5051)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  29. Vesleteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  30. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 gene therapy active

    2 trials

  31. AVI-4020 Injection

    Sarepta Therapeutics

    West Nile Virus

    phase 1 small molecule completed

    1 trial

  32. AVI-4020 Injection

    Sarepta Therapeutics

    West Nile Fever

    phase 1 small molecule terminated

    1 trial

  33. AVI-4065 Injection

    Sarepta Therapeutics

    Encephalitis

    phase 1 small molecule completed

    1 trial

  34. AVI-4126 Injection (RESTEN-NG®)

    Sarepta Therapeutics

    Neoplasms

    phase 1 small molecule completed

    1 trial

  35. AVI-6003

    Sarepta Therapeutics

    Marburg Hemorrhagic Fever

    phase 1 small molecule completed

    1 trial

  36. AVI-7100

    Sarepta Therapeutics

    Influenza

    phase 1 small molecule terminated

    1 trial

  37. AVI-7288

    Sarepta Therapeutics

    Marburg Hemorrhagic Fever

    phase 1 small molecule completed

    1 trial

  38. AVI-7537

    Sarepta Therapeutics

    Ebola Hemorrhagic Fever

    phase 1 small molecule terminated

    1 trial

  39. Idefirix 11 mg powder for concentrate for solution for infusion, Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne muscular dystrophy (DMD)

    phase 1 small molecule active

    1 trial

  40. Placebo

    Sarepta Therapeutics

    Ebola Hemorrhagic Fever

    phase 1 small molecule completed

    1 trial

  41. SRP-1005

    Sarepta Therapeutics

    Huntington's Disease

    phase 1 small molecule active

    1 trial

  42. SRP-6004

    Sarepta Therapeutics

    Limb Girdle Muscular Dystrophy

    phase 1 gene therapy terminated

    1 trial

  43. SRP-9004

    Sarepta Therapeutics

    Limb Girdle Muscular Dystrophy

    phase 1 small molecule terminated

    1 trial

  44. rAAVrh74.MHCK7.DYSF.DV

    Sarepta Therapeutics

    Dysferlinopathy

    phase 1 small molecule completed

    1 trial

  45. ELEVIDYS

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    approved small molecule active

    1 trial

  46. Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    approved small molecule terminated

    1 trial

Frequently asked questions

How many pipeline programs does Sarepta Therapeutics have?

46 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.